HealthQuill Schizophrenia
Bristol Myers Squibb will buy US-based biotech company, Karuna Therapeutics for $14 billion to expand its neuroscience portfolio, the companies announced.
Drugs Health Pharma

Bristol Myers to acquire Karuna Therapeutics for $14 billion

HQ Team December 23, 2023: Bristol Myers Squibb will buy US-based biotech company, Karuna Therapeutics for $14 billion to expand its neuroscience portfolio,.

Read More
The European Union has announced a 1.23 billion euro initiative to prevent mental health issues and find affordable treatments for its 84 million patients in the bloc.
Drugs Health Pharma

KarXT by Karuna Therapeutics offers hope for improved schizophrenia management

HQ Team, December 18, 2023: For individuals grappling with schizophrenia, the road to treatment is often marked by a lifelong commitment to antipsychotic.

Read More
At least 30% of cases of schizophrenia in young adults could have been staved off in Denmark by preventing cannabis use disorder, a study of more the six million people revealed.
Drugs Health Medical Pharma

Cannabis disorder prevention can obviate 30% schizophrenia cases in Denmark: Study 

HQ Team May 8, 2023: At least 30% of cases of schizophrenia in young adults could have been staved off in Denmark by.

Read More
US-based Merck will buy Prometheus Biosciences for about 10.8 billion to shore up its immunology portfolio to shield itself from eventual revenue loss as patents on its cancer immunotherapy Keytruda expires by the end of the decade.
Drugs Pharma

Merck to acquire Prometheus for $10.8 billion to step up immunology presence

HQ Team April 17, 2023: US-based Merck will buy Prometheus Biosciences for about 10.8 billion to shore up its immunology portfolio to shield itself from.

Read More
X